Skip to content
    Viking Global Investors logo

    Viking Global Investors

    Stamford, Connecticut, United StatesFounded 1999
    vikingglobal.comLinkedIn

    Viking Global Investors is an American investment management firm headquartered in Stamford, Connecticut, specializing in long-short equity, long-only equity, private equity, credit, and structured capital strategies. Founded in 1999, the firm manages approximately $52 billion of capital across public and private markets.

    39% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (4 deals in the last 12 months vs 6 prior). Average disclosed round size is $120.2M (across 178 rounds with reported amounts).

    Find people at Viking Global Investors on Goldilocks AI

    Portfolio

    127

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    4

    Team

    BR

    Brandan Rivard

    Managing Director

    BK

    Brent Kirshner

    Managing Director

    DT

    David Truetzel

    Managing Director

    HR

    Hans Reuter

    Managing Director

    KH

    Karim Helmy

    Managing Director

    RN

    Rohan Nirody

    Managing Director

    AS

    Alexandra Shoemaker

    Foundation Executive Director

    MD

    Martha Dabagian

    Director of Recruiting and Talent Development

    EN

    Emily Nolop

    Principal

    ES

    Erina Shan

    Principal

    HH

    Hans Halvorsen

    Principal

    JR

    Jason Rostovsky

    Principal

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    196 investments
    CompanyRoundAmountDate
    City Therapeutics logoCity TherapeuticsSeries B$99.5MJun 2026
    WWomen's Health, Sports & Performance InstituteUnknown—Jan 2026
    AlphaSense logoAlphaSenseGrowth$100MJan 2026
    AlphaSense logoAlphaSenseSeries C$350MJan 2026
    VeraDermics logoVeraDermicsSeries C—Oct 2025
    OOruka Therapeutics IncUnknown$180MSep 2025
    Antheia logoAntheiaSeries C$56MJun 2025
    Canopy logoCanopySeries C$70MApr 2025
    Neurona Therapeutics logoNeurona TherapeuticsUnknown$102MApr 2025
    Star Therapeutics logoStar TherapeuticsSeries D$125MJan 2025
    AssetWatch logoAssetWatchSeries C$75MJan 2025
    Damora Therapeutics logoDamora TherapeuticsUnknown$284.9MJan 2025
    SStar TxSeries D$125MJan 2025
    CCanopySeries C$70MJan 2025
    Neurona logoNeuronaSeries A$102MJan 2025
    Metsera logoMetseraSeries B—Nov 2024
    Triveni Bio logoTriveni BioSeries B$115MOct 2024
    TTriveniSeries B$115MOct 2024
    Magenta Medical logoMagenta MedicalGrowth$105MJul 2024
    Antheia logoAntheiaUnknown$17MJul 2024
    AlphaSense logoAlphaSenseGrowth$650MJun 2024
    Canopy logoCanopyUnknown$35MMay 2024
    Diagonal Therapeutics logoDiagonal TherapeuticsSeries A$128MApr 2024
    Neurona Therapeutics logoNeurona TherapeuticsUnknown$120MFeb 2024
    Valsoft logoValsoftGrowth—Jan 2024
    Page 1 of 8

    Top Co-Investors

    Cormorant Asset Management21 shared
    Perceptive Advisors21 shared
    RA Capital Management16 shared
    OrbiMed14 shared
    Casdin Capital14 shared
    Andreessen Horowitz13 shared
    Wellington Management13 shared
    Franklin Templeton12 shared
    Redmile Group11 shared
    T. Rowe Price10 shared
    General Atlantic10 shared
    BlackRock Private Equity Partners10 shared
    Logos Capital10 shared
    Venrock Healthcare Capital Partners10 shared
    Fidelity Investments9 shared
    Alexandria Venture Investments9 shared
    Rock Springs Capital9 shared
    F-Prime Capital8 shared
    Avidity Partners8 shared
    S2G Ventures7 shared

    Last updated: 7 October 2026